Cytotoxic Therapies Market to 2017 – Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion

GBI Research, the leading business intelligence provider, has released its latest research, “Cytotoxic Therapies Market to 2017 - Launch of Next Generation Camptothecin Analogues Will Help Offset Revenue Loss due to Generic Erosion”, which provides insights into the cytotoxic therapies market until 2017 for eight oncology indications. The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts. The report provides an in-depth analysis of the major oncology indications, including breast cancer, cervical cancer, colorectal cancer, non-Hodgkin lymphoma, head and neck cancer, non-small cell lung cancer, ovarian cancer and prostate cancer. The report examines the global oncology disease treatment usage patterns. In addition, the geographical distribution of cytotoxic therapies and markets across the US, the top five countries of Europe and Japan is provided in the report. The report also includes insights into the cytotoxic therapies R&D product pipeline and explores the competitive landscape, including major players in the cytotoxic therapies market. Finally, the report also includes analysis on Mergers and Acquisitions (M&As) and licensing agreements that have taken place in the cytotoxic therapies market.

In 2010, the cytotoxic therapies market for eight major oncology indications was estimated at $10.1 billion, indicating a compound annual growth rate (CAGR) of 5.8% since 2002. GBI Research forecasts the market to decline marginally at a CAGR of (0.1%) between 2010 and 2017, to record a sales value of $10.1 billion by 2017. The eight indications covered are breast cancer, cervical cancer, colorectal cancer, head and neck cancer, non-Hodgkin lymphoma, non-small cell lung cancer, ovarian cancer, and prostate cancer. The growth in major markets such as the US, the top five countries of Europe, and Japan, was driven mainly by the increasing prevalence and prescription population, and the combination of cytotoxic medicines with biologics, while the overall decline in market value is a result of patent expiries in the forecast period and subsequent reduction in annual cost of therapy.

The US was the leading geography, with an estimated sales value of $5.5 billion and an approximate share of 55%. The US market is expected to decline at a rate of (1.7%) between 2010 and 2017, to record a sales value of $4.9 billion in 2017. The top five countries of Europe together contributed to sales worth $3.3 billion in 2010, accounting for an approximate global share of 32.4%. The top five countries of Europe are expected to record sales worth $3.8 billion by the year 2017, registering a growth rate of 2%. Japan, in 2010, contributed $1.3 billion to the global market, increasing at a CAGR of 4.5% from 2002. It accounts for an approximate share of 12.6%. Decreasing at a rate of (1.1%) between 2010 and 2017, the market is expected to record sales worth $1.2 billion by 2017.

Scope

• Data and analysis on the cytotoxic therapies market in the leading geographies of the world – the US, the UK, Germany, France, Italy, Spain, and Japan.
• Annualized market data for the cytotoxic therapies market from 2002 to 2010, with forecasts to 2017.
• Market data on the geographical landscape and therapeutic landscape, including market size, market share, annual cost of therapy, sales volume, and treatment usage patterns such as disease population, treatment seeking population, diagnosis population and prescription population.
• Key drivers and restraints that have had a significant impact on the market.
• The competitive landscape of the global cytotoxic therapies market, including top companies benchmarking. The key companies studied in this report are Sanofi, Eli Lilly, Takeda Pharmaceuticals and Roche
• Key M&A activities and licensing agreements that took place in 2008 and 2011 in the cytotoxic therapies market.

Reasons to buy

• Align your product portfolio to the markets with high growth potential.
• Build effective strategies to launch their pipeline products by identifying potential geographies.
• Exploit in-licensing and out-licensing opportunities by identifying products that might fill their portfolio gaps.
• Develop key strategic initiatives by studying the key strategies of top competitors.
• Devise a more tailored country strategy through the understanding of key drivers and barriers and market potential of each indication.
• Develop market-entry and market expansion strategies by identifying the geographic markets poised for strong growth.
• Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules which are safer and more efficacious.

Table of Contents

1 Table of Contents 3
1.1 List of Tables 7
1.2 List of Figures 11

2 Cytotoxic Therapies Market to 2017 - Introduction 14
2.1 GBI Research Report Guidance 15

3 Cytotoxic Therapies Market to 2017 - Market Overview 16
3.1 Introduction 16
3.1.1 Revenue 16
3.1.2 Annual Cost of Therapy 19
3.1.3 Treatment Usage Pattern 20
3.2 Drivers and Barriers for the Global Cytotoxic Therapies Market 22
3.2.1 Drivers for the Global Cytotoxic Therapies Market 22
3.2.2 Barriers for the Global Cytotoxic Therapies Market 23

4 Cytotoxic Therapies Market to 2017 - Geographical Landscape 24
4.1 Geographical Segmentation 24
4.2 The US 26
4.2.1 Revenue 26
4.2.2 Annual Cost of Therapy 27
4.2.3 Treatment Usage Pattern 28
4.2.4 Drivers and Barriers for the Cytotoxic Therapies Market in the US 30
4.3 Top Five Countries of Europe 32
4.3.1 Revenue 32
4.3.2 Annual Cost of Therapy 33
4.3.3 Treatment Usage Pattern 34
4.3.4 Drivers and Barriers for the Cytotoxic Therapies Market in the Top Five Countries of Europe 36
4.4 Japan 38
4.4.1 Revenue 38
4.4.2 Annual Cost of Therapy 39
4.4.3 Treatment Usage Pattern 40
4.4.4 Drivers and Barriers for the Cytotoxic Therapies Market in Japan 42

5 Cytotoxic Therapies Market to 2017 - Therapeutic Landscape 44
5.1 Breast Cancer 44
5.1.1 Introduction 44
5.1.2 Survival Rates by Stage 46
5.1.3 Symptoms 46
5.1.4 Treatment Flow 47
5.1.5 Revenue 50
5.1.6 Annual Cost of Therapy 53
5.1.7 Treatment Usage Pattern 54
5.1.8 Drivers and Barriers 56
5.2 Cervical Cancer 57
5.2.1 Introduction 57
5.2.2 Survival Rates 58
5.2.3 Symptoms 59
5.2.4 Treatment Flow 59
5.2.5 Revenue 60
5.2.6 Annual Cost of Therapy 63
5.2.7 Treatment Usage Pattern 64
5.2.8 Drivers and Barriers 66
5.3 Colorectal Cancer 67
5.3.1 Introduction 67
5.3.2 Survival Rates by Stage 68
5.3.3 Symptoms 68
5.3.4 Treatment Flow 69
5.3.5 Revenue 72
5.3.6 Annual Cost of Therapy 75
5.3.7 Treatment Usage Pattern 76
5.3.8 Drivers and Barriers 78
5.4 Head and Neck Cancer 79
5.4.1 Introduction 79
5.4.2 Survival Rates 80
5.4.3 Symptoms 80
5.4.4 Treatment Flow 81
5.4.5 Revenue 82
5.4.6 Annual Cost of Therapy 86
5.4.7 Treatment Usage Pattern 87
5.4.8 Drivers and Barriers 89
5.5 Non-Hodgkin Lymphoma 90
5.5.1 Introduction 90
5.5.2 Survival Rates by Stage 91
5.5.3 Symptoms 91
5.5.4 Treatment Flow 92
5.5.5 Revenue 93
5.5.6 Annual Cost of Therapy 96
5.5.7 Treatment Usage Pattern 97
5.5.8 Drivers and Barriers 99
5.6 Non-Small Cell Lung Cancer (NSCLC) 100
5.6.1 Introduction 100
5.6.2 Survival Rates by Stage 101
5.6.3 Symptoms 101
5.6.4 Treatment Flow 102
5.6.5 Revenue 104
5.6.6 Annual Cost of Therapy 107
5.6.7 Treatment Usage Pattern 108
5.6.8 Drivers and Barriers 110
5.7 Ovarian Cancer 111
5.7.1 Introduction 111
5.7.2 Survival Rates 111
5.7.3 Symptoms 112
5.7.4 Treatment Flow 112
5.7.5 Revenue 113
5.7.6 Annual Cost of Therapy 116
5.7.7 Treatment Usage Pattern 117
5.7.8 Drivers and Barriers 119
5.8 Prostate Cancer 120
5.8.1 Introduction 120
5.8.2 Survival Rates 121
5.8.3 Symptoms 121
5.8.4 Treatment Flow 122
5.8.5 Revenue 123
5.8.6 Annual Cost of Therapy 127
5.8.7 Treatment Usage Pattern 128
5.8.8 Drivers and Barriers 130

6 Cytotoxic Therapies Market to 2017 - Pipeline Analysis 131
6.1 Introduction 131
6.2 Cytotoxic Therapies Market - Pipeline Assessment by Indication 133
6.2.1 Breast Cancer 133
6.2.2 Cervical Cancer 137
6.2.3 Colorectal Cancer 138
6.2.4 Head and Neck Cancer 143
6.2.5 Non-Hodgkin Lymphoma 146
6.2.6 Non-Small Cell Lung Cancer 149
6.2.7 Ovarian Cancer 153
6.2.8 Prostate Cancer 159
6.3 Profiles of Promising Molecules in the Cytotoxic Therapies Market 162
6.3.1 Eniluracil (ADH300004) 162
6.3.2 Karenitecin 163
6.3.3 Vintafolide (EC145) 164
6.3.4 Tavocept 165

7 Cytotoxic Therapies Market to 2017 - Competitive Lanscape 167
7.1 Sanofi 167
7.1.1 Company Overview 167
7.1.2 Marketed Products 168
7.1.3 SWOT Analysis 168
7.2 Eli Lilly & Company 169
7.2.1 Company Overview 169
7.2.2 Marketed Products 170
7.2.3 SWOT Analysis 171
7.3 Takeda Pharmaceutical Company Ltd. 172
7.3.1 Company Overview 172
7.3.2 Marketed Products 173
7.3.3 SWOT Analysis 173
7.4 F. Hoffmann-La Roche Ltd. 174
7.4.1 Company Overview 174
7.4.2 Marketed Products 175
7.4.3 SWOT Analysis 175

8 Cytotoxic Therapies Market to 2017 - Strategic Consolidations 176
8.1 Deals by Type 176
8.2 Deals by Indication 177
8.3 Mergers and Acquisitions 178
8.3.1 Segmentation by Year 178
8.3.2 Segmentation by Value 179
8.3.3 Segmentation by Geography 180
8.3.4 Major Merger and Acquisition Deals 180
8.4 Co-Development Deals 181
8.4.1 Segmentation by Year 182
8.4.2 Segmentation by Geography 183
8.4.3 Major Co-Development Deals 184
8.5 Licensing Deals 185
8.5.1 Segmentation by Year 186
8.5.2 Segmentation by Value 187
8.5.3 Segmentation by Geography 188
8.5.4 Major Licensing Deals 190

9 Cytotoxic Therapies Market to 2017 - Appendix 191
9.1 Market Definitions 191
9.2 Abbreviations 191
9.3 Sources 193
9.4 Research Methodology 194
9.4.1 Coverage 194
9.4.2 Secondary Research 194
9.4.3 Primary Research 194
9.4.4 Therapeutic Landscape 195
9.4.5 Market Size by Geography 197
9.4.6 Geographical Landscape 197
9.4.7 Pipeline Analysis 198
9.4.8 Competitive Landscape 198
9.4.9 Expert Panel Validation 198
9.5 Contact Us 198
9.6 Disclaimer 198

List of Tables

Table 1: Cytotoxic Therapies Market, Global, Revenue ($bn), 2002-2010 16
Table 2: Cytotoxic Therapies Market, Global, Revenue Forecasts ($bn), 2010-2017 16
Table 3: Cytotoxic Therapies Market, Global, Annual Cost of Therapy ($), 2002-2010 19
Table 4: Cytotoxic Therapies Market, Global, Annual Cost of Therapy ($), 2010-2017 19
Table 5: Cytotoxic Therapies Market, Global, Treatment Usage Pattern, Population (‘000), 2002-2010 20
Table 6: Cytotoxic Therapies Market, Global, Treatment Usage Pattern, Population (‘000), 2010-2017 21
Table 7: Cytotoxic Therapies Market, Global, Geographical Segmentation ($m), 2002-2010 24
Table 8: Cytotoxic Therapies Market, Global, Geographical Segmentation ($m), 2010-2017 24
Table 9: Cytotoxic Therapies Market, The US, Revenue ($bn), 2002-2010 26
Table 10: Cytotoxic Therapies Market, The US, Revenue Forecasts ($bn), 2010-2017 26
Table 11: Cytotoxic Therapies Market, The US, Annual Cost of Therapy ($), 2002-2010 27
Table 12: Cytotoxic Therapies Market, The US, Annual Cost of Therapy ($), 2010-2017 27
Table 13: Cytotoxic Therapies Market, The US, Treatment Usage Pattern, Population (‘000), 2002-2010 28
Table 14: Cytotoxic Therapies Market, The US, Treatment Usage Pattern, Population (‘000), 2010-2017 29
Table 15: Cytotoxic Therapies Market, Top Five Countries of Europe, Revenue ($m), 2002-2010 32
Table 16: Cytotoxic Therapies Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2010-2017 32
Table 17: Cytotoxic Therapies Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2010 33
Table 18: Cytotoxic Therapies Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2010-2017 33
Table 19: Cytotoxic Therapies Market, Top Five Countries of Europe, Treatment Usage Pattern, Population (‘000), 2002-2010 34
Table 20: Cytotoxic Therapies Market, Top Five Countries of Europe, Treatment Usage Pattern, Population (‘000), 2010-2017 35
Table 21: Cytotoxic Therapies Market, Japan, Revenue ($m), 2002-2010 38
Table 22: Cytotoxic Therapies Market, Japan, Revenue Forecasts ($m), 2010-2017 38
Table 23: Cytotoxic Therapies Market, Japan, Annual Cost of Therapy ($), 2002-2010 39
Table 24: Cytotoxic Therapies Market, Japan, Annual Cost of Therapy ($), 2010-2017 39
Table 25: Cytotoxic Therapies Market, Japan, Treatment Usage Pattern, Population (‘000), 2002-2010 40
Table 26: Cytotoxic Therapies Market, Japan, Treatment Usage Pattern, Population (‘000), 2010-2017 41
Table 27: Cytotoxic Therapies Market, Global, Breast Cancer, Cancer Categorized by Disease Stage, 2011 44
Table 28: Cytotoxic Therapies Market, Global, Breast Cancer, Stage Distribution and Survival For Patients in the US (%), 2001-2007 46
Table 29: Cytotoxic Therapies Market, Global, Breast Cancer, Revenue ($m), 2002-2010 50
Table 30: Cytotoxic Therapies Market, Global, Breast Cancer, Revenue Forecasts ($m), 2010-2017 50
Table 31: Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m), 2002-2010 51
Table 32: Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m), 2010-2017 52
Table 33: Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2002-2010 53
Table 34: Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2010-2017 53
Table 35: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Usage Pattern, Population (‘000), 2002-2010 54
Table 36: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Usage Pattern, Population (‘000), 2010-2017 55
Table 37: Cytotoxic Therapies Market, Global, Cervical Cancer, Clinical Staging, 2011 58
Table 38: Cytotoxic Therapies Market, Global, Cervical Cancer, Stage Distribution and Survival For Patients in the US (%), 2001-2007 58
Table 39: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Flow 59
Table 40: Cytotoxic Therapies Market, Global, Cervical Cancer, Revenue ($m), 2002-2010 60
Table 41: Cytotoxic Therapies Market, Global, Cervical Cancer, Revenue Forecast ($m), 2010-2017 60
Table 42: Cytotoxic Therapies Market, Global, Cervical Cancer, Geographical Segmentation ($m), 2002-2010 61
Table 43: Cytotoxic Therapies Market, Global, Cervical Cancer, Geographical Segmentation ($m), 2010-2017 62
Table 44: Cytotoxic Therapies Market, Global, Cervical Cancer, Annual Cost of Therapy ($), 2002-2010 63
Table 45: Cytotoxic Therapies Market, Global, Cervical Cancer, Annual Cost of Therapy ($), 2010-2017 63
Table 46: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern, Population (‘000), 2002-2010 64
Table 47: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern, Population (‘000), 2010-2017 65
Table 48: Cytotoxic Therapies Market, Global, Colorectal Cancer, Cancer Categorized by Disease Stage 68
Table 49: Cytotoxic Therapies Market, Global, Colorectal Cancer, Stage Distribution and Five-Year Relative Survival by Stage at Diagnosis for Patients in the US (%), 2001-2007 68
Table 50: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue ($bn), 2002-2010 72
Table 51: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue Forecasts ($bn), 2010-2017 72
Table 52: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2002-2010 73
Table 53: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2010-2017 74
Table 54: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($), 2002-2010 75
Table 55: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($), 2010-2017 75
Table 56: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Usage Pattern, Population (‘000), 2002-2010 77
Table 57: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Usage Pattern, Population (‘000), 2010-2017 77
Table 58: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Staging, 2011 79
Table 59: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Stage Distribution and Survival For Patients in the US (%), 1998-2001 80
Table 60: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Revenue ($m), 2002-2010 82
Table 61: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Revenue Forecasts ($m), 2010-2017 82
Table 62: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical Segmentation ($m), 2002-2010 84
Table 63: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical Segmentation ($m), 2010-2017 84
Table 64: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy ($), 2002-2010 86
Table 65: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy ($), 2010-2017 86
Table 66: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Usage Pattern, Population (‘000), 2002-2010 87
Table 67: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Usage Pattern, Population (‘000), 2010-2017 88
Table 68: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Cancer Categorized by Disease Stage 90
Table 69: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Stage Distribution and 5-Year Survival Rates by Stage at Diagnosis for Patients in the US (%), 2001-2007 91
Table 70: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Revenue ($m), 2002-2010 93
Table 71: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Revenue Forecasts ($m), 2010-2017 93
Table 72: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical Segmentation ($m), 2002-2010 94
Table 73: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical Segmentation ($m), 2010-2017 95
Table 74: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy ($), 2002-2010 96
Table 75: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy ($), 2010-2017 96
Table 76: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Usage Pattern, Population (‘000), 2002-2010 97
Table 77: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Usage Pattern, Population (‘000), 2010-2017 98
Table 78: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Cancer Categorized by Disease Stage 100
Table 79: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Stage Distribution and Survival for Lung Cancer Patients in the US (%), 2000-2007 101
Table 80: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Revenue ($m), 2002-2010 104
Table 81: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Revenue Forecasts ($m), 2010-2017 104
Table 82: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical Segmentation ($m), 2002-2010 105
Table 83: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical Segmentation ($m), 2010-2017 106
Table 84: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of Therapy ($), 2002-2010 107
Table 85: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of Therapy ($), 2010-2017 107
Table 86: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Usage Pattern, Population (‘000), 2002-2010 108
Table 87: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Usage Pattern, Population (‘000), 2010-2017 109
Table 88: Cytotoxic Therapies Market, Global, Ovarian Cancer, Surgical Staging, 2011 111
Table 89: Cytotoxic Therapies Market, Global, Ovarian Cancer, Stage Distribution and Survival for Patients in the US (%), 2001-2007 111
Table 90: Cytotoxic Therapies Market, Global, Ovarian Cancer, Post-Operative Treatment, 2011 112
Table 91: Cytotoxic Therapies Market, Global, Ovarian Cancer, Revenue ($m), 2002-2010 113
Table 92: Cytotoxic Therapies Market, Global, Ovarian Cancer, Revenue Forecasts ($m), 2010-2017 113
Table 93: Cytotoxic Therapies Market, Global, Ovarian Cancer, Geographical Segmentation ($m), 2002-2010 114
Table 94: Cytotoxic Therapies Market, Global, Ovarian Cancer, Geographical Segmentation ($m), 2010-2017 115
Table 95: Cytotoxic Therapies Market, Global, Ovarian Cancer, Annual Cost of Therapy ($), 2002-2010 116
Table 96: Cytotoxic Therapies Market, Global, Ovarian Cancer, Annual Cost of Therapy ($), 2010-2017 116
Table 97: Cytotoxic Therapies Market, Global, Ovarian Cancer, Treatment Usage Pattern, Population (‘000), 2002-2010 117
Table 98: Cytotoxic Therapies Market, Global, Ovarian Cancer, Treatment Usage Pattern, Population (‘000), 2010-2017 118
Table 99: Cytotoxic Therapies Market, Global, Prostate Cancer, Cancer Characterized by Disease Stage 120
Table 100: Cytotoxic Therapies Market, Global, Prostate Cancer, Stage Distribution and Survival for Patients in the US (%), 2000-2007 121
Table 101: Cytotoxic Therapies Market, Global, Prostate Cancer, Revenue ($m), 2002-2010 123
Table 102: Cytotoxic Therapies Market, Global, Prostate Cancer, Revenue Forecasts ($m), 2010-2017 124
Table 103: Cytotoxic Therapies Market, Global, Prostate Cancer, Geographical Segmentation ($m), 2002-2010 125
Table 104: Cytotoxic Therapies Market, Global, Prostate Cancer, Geographical Segmentation ($m), 2010-2017 125
Table 105: Cytotoxic Therapies Market, Global, Prostate Cancer, Annual Cost of Therapy ($), 2002-2010 127
Table 106: Cytotoxic Therapies Market, Global, Prostate Cancer, Annual Cost of Therapy ($), 2010-2017 128
Table 107: Cytotoxic Therapies Market, Global, Prostate Cancer Treatment Usage Pattern, Population (‘000), 2002-2010 129
Table 108: Cytotoxic Therapies Market, Global, Prostate Cancer Treatment Usage Pattern, Population (‘000), 2010-2017 129
Table 109: Cytotoxic Therapies Market, Global, Breast Cancer, Phase III Pipeline, 2011 134
Table 110: Cytotoxic Therapies Market, Global, Breast Cancer, Phase II Pipeline, 2011 134
Table 111: Cytotoxic Therapies Market, Global, Breast Cancer, Phase I Pipeline, 2011 135
Table 112: Cytotoxic Therapies Market, Global, Breast Cancer, Pre-Clinical Phase Pipeline, 2011 136
Table 113: Cytotoxic Therapies Market, Global, Breast Cancer, Discovery Phase Pipeline, 2011 136
Table 114: Cytotoxic Therapies Market, Global, Cervical Cancer, Phase III Pipeline, 2011 137
Table 115: Cytotoxic Therapies Market, Global, Cervical Cancer, Phase II Pipeline, 2011 137
Table 116: Cytotoxic Therapies Market, Global, Cervical Cancer, Phase I Pipeline, 2011 138
Table 117: Cytotoxic Therapies Market, Global, Cervical Cancer, Pre-Clinical Phase Pipeline, 2011 138
Table 118: Cytotoxic Therapies Market, Global, Colorectal Cancer, Phase III Pipeline, 2011 139
Table 119: Cytotoxic Therapies Market, Global, Colorectal Cancer, Phase II Pipeline, 2011 139
Table 120: Cytotoxic Therapies Market, Global, Colorectal Cancer, Phase I Pipeline, 2011 141
Table 121: Cytotoxic Therapies Market, Global, Colorectal Cancer, Pre-Clinical Phase Pipeline, 2011 142
Table 122: Cytotoxic Therapies Market, Global, Colorectal Cancer, Discovery Phase Pipeline, 2011 142
Table 123: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Phase III Pipeline, 2011 144
Table 124: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Phase II Pipeline, 2011 144
Table 125: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Phase I Pipeline, 2011 145
Table 126: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Pre-Clinical Phase Pipeline, 2011 145
Table 127: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Phase III Pipeline, 2011 146
Table 128: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Phase II Pipeline, 2011 147
Table 129: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Phase I Pipeline, 2011 148
Table 130: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Phase III Pipeline, 2011 150
Table 131: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Phase II Pipeline, 2011 151
Table 132: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Phase I Pipeline, 2011 151
Table 133: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Pre-Clinical Phase Pipeline, 2011 152
Table 134: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Discovery Phase Pipeline, 2011 152
Table 135: Cytotoxic Therapies Market, Global, Ovarian Cancer, Phase III Pipeline, 2011 154
Table 136: Cytotoxic Therapies Market, Global, Ovarian Cancer, Phase II Pipeline, 2011 155
Table 137: Cytotoxic Therapies Market, Global, Ovarian Cancer, Phase I Pipeline, 2011 157
Table 138: Cytotoxic Therapies Market, Global, Ovarian Cancer, Pre-Clinical Phase Pipeline, 2011 158
Table 139: Cytotoxic Therapies Market, Global, Ovarian Cancer, Discovery Phase Pipeline, 2011 159
Table 140: Cytotoxic Therapies Market, Global, Prostate Cancer, Phase III Pipeline, 2011 160
Table 141: Cytotoxic Therapies Market, Global, Prostate Cancer, Phase II Pipeline, 2011 160
Table 142: Cytotoxic Therapies Market, Global, Prostate Cancer, Phase I Pipeline, 2011 161
Table 143: Cytotoxic Therapies Market, Global, Prostate Cancer, Pre-Clinical Phase Pipeline, 2011 161
Table 144: Cytotoxic Therapies Market, Global, M&A Deals, 2008-2011 180
Table 145: Cytotoxic Therapies Market, Global, Co-Development Deals, 2008-2011 184
Table 146: Cytotoxic Therapies Market, Global, Licensing Deals, 2008-2011 189

List of Figures

Figure 1: Cytotoxic Therapies Market, Global, Revenue Forecasts ($bn), 2002-2017 16
Figure 2: Cytotoxic Therapies Market, Global, Branded and Generic Market Share (%), 2010 and 2017 17
Figure 3: Cytotoxic Therapies Market, Global, Annual Cost of Therapy ($), 2002-2017 19
Figure 4: Cytotoxic Therapies Market, Global, Treatment Usage Pattern, Population (‘000), 2002-2017 20
Figure 5: Cytotoxic Therapies Market, Global, Drivers and Barriers 22
Figure 6: Cytotoxic Therapies Market, Global, Geographical Segmentation ($m), 2002-2017 24
Figure 7: Cytotoxic Therapies Market, The US, Revenue Forecasts ($bn), 2002-2017 26
Figure 8: Cytotoxic Therapies Market, The US, Annual Cost of Therapy ($), 2002-2017 27
Figure 9: Cytotoxic Therapies Market, The US, Treatment Usage Pattern, Population (‘000), 2002-2017 28
Figure 10: Cytotoxic Therapies Market, The US, Drivers and Barriers 30
Figure 11: Cytotoxic Therapies Market, Top Five Countries of Europe, Revenue Forecasts ($m), 2002-2017 32
Figure 12: Cytotoxic Therapies Market, Top Five Countries of Europe, Annual Cost of Therapy ($), 2002-2017 33
Figure 13: Cytotoxic Therapies Market, Top Five Countries of Europe, Treatment Usage Pattern, Population (‘000), 2002-2017 34
Figure 14: Cytotoxic Therapies Market, Top Five Countries of Europe, Drivers and Barriers 36
Figure 15: Cytotoxic Therapies Market, Japan, Revenue Forecasts ($m), 2002-2017 38
Figure 16: Cytotoxic Therapies Market, Japan, Annual Cost of Therapy ($), 2002-2017 39
Figure 17: Cytotoxic Therapies Market, Japan, Treatment Usage Pattern, Population (‘000), 2002-2017 40
Figure 18: Cytotoxic Therapies Market, Japan, Drivers and Barriers 42
Figure 19: Cytotoxic Therapies Market, Global, Breast Cancer, Types of Breast Cancer, 2011 45
Figure 20: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage 0 47
Figure 21: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage I and II 47
Figure 22: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage III 48
igure 23: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Flow Algorithm, Stage IV 48
Figure 24: Cytotoxic Therapies Market, Global, Breast Cancer, Revenue Forecasts ($m), 2002-2017 50
Figure 25: Cytotoxic Therapies Market, Global, Breast Cancer, Geographical Segmentation ($m), 2002-2017 51
Figure 26: Cytotoxic Therapies Market, Global, Breast Cancer, Branded and Generic Market Share (%), 2010 and 2017 52
Figure 27: Cytotoxic Therapies Market, Global, Breast Cancer, Annual Cost of Therapy ($), 2002-2017 53
Figure 28: Cytotoxic Therapies Market, Global, Breast Cancer, Treatment Usage Pattern, Population (‘000), 2002-2017 54
Figure 29: Cytotoxic Therapies Market, Global, Breast Cancer, Drivers and Barriers 56
Figure 30: Cytotoxic Therapies Market, Global, Cervical Cancer, Revenue Forecasts ($m), 2002-2017 60
Figure 31: Cytotoxic Therapies Market, Global, Cervical Cancer, Geographical Segmentation ($m), 2002-2017 61
Figure 32: Cytotoxic Therapies Market, Global, Cervical Cancer, Branded and Generic Market Share (%), 2010 and 2017 62
Figure 33: Cytotoxic Therapies Market, Global, Cervical Cancer, Annual Cost of Therapy ($), 2002-2017 63
Figure 34: Cytotoxic Therapies Market, Global, Cervical Cancer, Treatment Usage Pattern, Population (‘000), 2002-2017 64
Figure 35: Cytotoxic Therapies Market, Global, Cervical Cancer, Drivers and Barriers 66
Figure 36: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Flow Algorithm, Colon Cancer, Part-1 69
Figure 37: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Flow Algorithm, Colon Cancer, Part-2 70
Figure 38: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Flow Algorithm, Rectal Cancer, 2011 71
Figure 39: Cytotoxic Therapies Market, Global, Colorectal Cancer, Revenue Forecasts ($bn), 2002-2017 72
Figure 40: Cytotoxic Therapies Market, Global, Colorectal Cancer, Geographical Segmentation ($m), 2002-2017 73
Figure 41: Cytotoxic Therapies Market, Global, Colorectal Cancer, Branded and Generic Market Share (%), 2010 and 2017 74
Figure 42: Cytotoxic Therapies Market, Global, Colorectal Cancer, Annual Cost of Therapy ($), 2002-2017 75
Figure 43: Cytotoxic Therapies Market, Global, Colorectal Cancer, Treatment Usage Pattern, Population (‘000), 2002-2017 76
Figure 44: Cytotoxic Therapies Market, Global, Colorectal Cancer, Drivers and Barriers 78
Figure 45: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Flow Algorithm 81
Figure 46: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Revenue Forecasts ($m), 2002-2017 82
Figure 47: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Geographical Segmentation ($m), 2002-2017 83
Figure 48: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Branded and Generic Market Share (%), 2010 and 2017 85
Figure 49: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Annual Cost of Therapy ($), 2002-2017 86
Figure 50: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Treatment Usage Pattern, Population (‘000), 2002-2017 87
Figure 51: Cytotoxic Therapies Market, Global, Head and Neck Cancer, Drivers and Barriers 89
Figure 52: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Classification 91
Figure 53: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Flow Algorithm 92
Figure 54: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Revenue Forecasts ($m), 2002-2017 93
Figure 55: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Geographical Segmentation ($m), 2002-2017 94
Figure 56: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Branded and Generic Market Share (%), 2010 and 2017 95
Figure 57: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Annual Cost of Therapy ($), 2002-2017 96
Figure 58: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Treatment Usage Pattern, Population (‘000), 2002-2017 97
Figure 59: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma, Drivers and Barriers 99
Figure 60: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Flow Algorithm, Part 1 102
Figure 61: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Flow Algorithm, Part 2 103
Figure 62: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Revenue Forecasts ($m), 2002-2017 104
Figure 63: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Geographical Segmentation ($m), 2002-2017 105
Figure 64: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Branded and Generic Market Share (%), 2010 and 2017 106
Figure 65: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Annual Cost of Therapy ($), 2002-2017 107
Figure 66: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Treatment Usage Pattern, Population (‘000), 2002-2017 108
Figure 67: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer, Drivers and Barriers 110
Figure 68: Cytotoxic Therapies Market, Global, Ovarian Cancer, Revenue Forecasts ($m), 2002-2017 113
Figure 69: Cytotoxic Therapies Market, Global, Ovarian Cancer, Geographical Segmentation ($m), 2002-2017 114
Figure 70: Cytotoxic Therapies Market, Global, Ovarian Cancer, Branded and Generic Market Share (%), 2010 and 2017 115
Figure 71: Cytotoxic Therapies Market, Global, Ovarian Cancer, Annual Cost of Therapy ($), 2002-2017 116
Figure 72: Cytotoxic Therapies Market, Global, Ovarian Cancer, Treatment Usage Pattern, Population (‘000), 2002-2017 117
Figure 73: Cytotoxic Therapies Market, Global, Ovarian Cancer, Drivers and Barriers 119
Figure 74: Cytotoxic Therapies Market, Global, Prostate Cancer, Treatment Flow Algorithm 122
Figure 75: Cytotoxic Therapies Market, Global, Prostate Cancer, Revenue Forecasts ($m), 2002-2017 123
Figure 76: Cytotoxic Therapies Market, Global, Prostate Cancer, Geographical Segmentation ($m), 2002-2017 124
Figure 77: Cytotoxic Therapies Market, Global, Prostate Cancer, Branded and Generic Market Share (%), 2010 and 2017 126
Figure 78: Cytotoxic Therapies Market, Global, Prostate Cancer, Annual Cost of Therapy ($), 2002-2017 127
Figure 79: Cytotoxic Therapies Market, Global, Prostate Cancer, Treatment Usage Pattern, Population (‘000), 2002-2017 128
Figure 80: Cytotoxic Therapies Market, Global, Prostate Cancer, Drivers and Barriers, 2011 130
Figure 81: Cytotoxic Therapies Market, Global, R&D Pipeline by Indication, 2011 131
Figure 82: Cytotoxic Therapies Market, Global, R&D Pipeline by Phase, 2011 132
Figure 83: Cytotoxic Therapies Market, Global, Breast Cancer R&D Pipeline, 2011 133
Figure 84: Cytotoxic Therapies Market, Global, Cervical Cancer R&D Pipeline, 2011 137
Figure 85: Cytotoxic Therapies Market, Global, Colorectal Cancer R&D Pipeline, 2011 138
Figure 86: Cytotoxic Therapies Market, Global, Head and Neck Cancer R&D Pipeline, 2011 143
Figure 87: Cytotoxic Therapies Market, Global, Non-Hodgkin Lymphoma R&D Pipeline, 2011 146
Figure 88: Cytotoxic Therapies Market, Global, Non-Small Cell Lung Cancer R&D Pipeline, 2011 149
Figure 89: Cytotoxic Therapies Market, Global, Ovarian Cancer R&D Pipeline, 2011 153
Figure 90: Cytotoxic Therapies Market, Global, Prostate Cancer R&D Pipeline, 2011 159
Figure 91: Cytotoxic Therapies Market, Competitive Landscape, Sanofi, 2011 167
Figure 92: Cytotoxic Therapies Market, Competitive Landscape, Sanofi, SWOT, 2011 168
Figure 93: Cytotoxic Therapies Market, Competitive Landscape, Eli Lilly & Company, 2011 169
Figure 94: Cytotoxic Therapies Market, Competitive Landscape, Eli Lilly, SWOT, 2011 171
Figure 95: Cytotoxic Therapies Market, Competitive Landscape, Takeda Pharmaceuticals, 2011 172
Figure 96: Cytotoxic Therapies Market, Competitive Landscape, Takeda, SWOT, 2011 173
Figure 97: Cytotoxic Therapies Market, Competitive Landscape, Roche, 2011 174
Figure 98: Cytotoxic Therapies Market, Competitive Landscape, Hoffmann-La Roche, SWOT, 2011 175
Figure 99: Cytotoxic Therapies Market, Global, Deals by Type, 2008-2011 176
Figure 100: Cytotoxic Therapies Market, Global, Deals by Indications, 2008-2011 177
Figure 101: Cytotoxic Therapies Market, Global, Mergers and Acquisitions, Segmentation By Year, 2008-2011 178
Figure 102: Cytotoxic Therapies Market, Global, Mergers and Acquisitions, Segmentation By Value, 2008-2011 179
Figure 103: Cytotoxic Therapies Market, Global, Co-Development Deals, By Indication (%), 2008-2011 181
Figure 104: Cytotoxic Therapies Market, Global, Co-Development Deals, Segmentation By Year, 2008-2011 182
Figure 105: Cytotoxic Therapies Market, Global, Co-Development Deals, Segmentation By Geography (%), 2008-2011 183
Figure 106: Cytotoxic Therapies Market, Global, Licensing Deals, By Indication (%), 2008-2011 185
Figure 107: Cytotoxic Therapies Market, Global, Licensing Deals, Segmentation By Year, 2008-2011 186
Figure 108: Cytotoxic Therapies Market, Global, Licensing Deals, Segmentation By Value (%), 2008-2011 187
Figure 109: Cytotoxic Therapies Market, Global, Licensing Deals, Segmentation By Geography (%), 2008-2011 188
Figure 110: GBI Research Market Forecasting Model 197